Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.
研究概览
详细说明
For patients with peripheral non-small cell lung cancer receiving stereotactic body radiation therapy, respiratory motion often causes target volume deviation and compromises dose accuracy to tumors and nearby organs at risk. Current standard immobilization methods have limited ability to stabilize deep breathing patterns. This single-center translational study uses an integrated body position and breath-holding device, enrolling 50 eligible patients who will undergo 4DCT scans both with and without the device while keeping their clinical SBRT treatment plan unchanged. We will compare tumor motion amplitude, target coverage, conformity index and organ dose parameters between the two scanning states, to verify the device's feasibility, safety and value in improving treatment precision, providing clinical evidence for wider application in lung SBRT.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Tianjin、中国、300000
- Tianjin Medical University Cancer Institute and Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Voluntarily participate and sign written informed consent
- Age ≥18 years, gender unlimited
- Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT
- Males or females of childbearing age willing to take contraceptive measures during the trial
- Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after
Exclusion Criteria:
- Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization.
- Currently participating or planning to participate in other clinical trials.
- Refuse or be unable to sign the informed consent form for this trial.
- Patients with central or ultra-central lung cancer.
- Patients planned to receive SBRT for multiple pulmonary lesions.
- Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single Arm - Novel Respiratory Immobilization
All enrolled patients receive 4DCT with and without the device |
A novel immobilization device used for respiratory motion management during lung stereotactic body radiation therapy |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Mean respiratory motion amplitude of GTV and organs at risk (OARs) measured on 4DCT before and after abdominal pressure immobilization
大体时间:through study completion, an average of 1 year
|
Respiratory motion amplitude (maximum displacement) of gross tumor volume (GTV) and organs at risk (OARs) will be contoured and extracted from pre-abdominal-pressure 4DCT and post-abdominal-pressure 4DCT. The difference in motion amplitude between the two states will be compared to evaluate the feasibility and effectiveness of the novel abdominal pressure positioning membrane for lung SBRT. |
through study completion, an average of 1 year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Conformity index (CI) of SBRT planning target volume (PTV)
大体时间:At the time of SBRT plan design, prior to treatment delivery
|
CI of PTV calculated from SBRT dose distribution after abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
|
Coverage of planning target volume (PTV)
大体时间:At the time of SBRT plan design, prior to treatment delivery
|
PTV coverage calculated from SBRT dose distribution after abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
|
Maximum relative dose at 2 cm outside the PTV boundary (D2cm)
大体时间:At the time of SBRT plan design, prior to treatment delivery
|
Percentage of maximum dose at the region 2 cm outside PTV boundary on SBRT plan |
At the time of SBRT plan design, prior to treatment delivery
|
|
Volume of normal ipsilateral lung receiving ≥20Gy,15Gy,10Gy and 5Gy (V20,V15, V10, V5)
大体时间:At the time of SBRT plan design, prior to treatment delivery
|
Dose-volume histogram parameters of normal treated lung from abdominal-pressure SBRT plan |
At the time of SBRT plan design, prior to treatment delivery
|
|
Maximum dose (Dmax) to organs at risk including spinal cord, heart and esophagus
大体时间:At the time of SBRT plan design, prior to treatment delivery
|
Dmax of OARs derived from SBRT dose plan under abdominal pressure immobilization |
At the time of SBRT plan design, prior to treatment delivery
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- bc20261997
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
This is an exploratory feasibility study, and no public sharing of individual patient data is planned.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.